EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial

Hans-Kittil Viermyr, Bente Halvorsen, Ellen Lund Sagen, Annika E Michelsen, Andreas Barrat-Due iD, Trine Kåsine iD, Katerina Nezvalova-Henriksen, Anne Ma Dyrhol-Riise, Nor‐Solidarity Consortium, Tøri Vigeland Lerum iD, Fredrik Müller, Kristian Tonby und 5 weitere

Journal of Internal Medicine · 2024

DOI: 10.1111/joim.13820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Hans-Kittil Viermyr und 16 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: COVID-19, Biomarkers, Viral Load, Hospitalization. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate temporal changes in the association between SARS‐CoV2 viral load (VL) and markers of inflammation during hospitalization, as well as the ability of these markers alone or in combination to predict severe outcomes.

Methods

Serial oropharyngeal and blood samples were obtained from hospitalized COVID‐19 patients ( n = 160). Levels of inflammatory markers and oropharyngeal VL were measured during hospitalization (admission, days 3–5, and days 7–10) and related to severe outcomes (respiratory failure/intensive care unit admission).

Results

Elevated admission levels of IL (interleukin)‐6, IL‐33, IL‐8, monocyte chemoattractant protein‐1 (MCP‐1), interferon‐γ‐induced protein 10 (IP‐10), IL‐1β, and IL‐1Ra were associated with severe outcomes during hospitalization. Although no inflammatory markers correlated with VL at baseline, there was a significant correlation between VL and levels of IP‐10 and MCP‐1 at days 3–5, accompanied by IL‐8 and IL‐6 at days 7–10. Finally, there was a seemingly additive effect of IP‐10, MCP‐1, and IL‐6 in predicting severe outcomes when combined with high VL at baseline.

Conclusions

An increasing number of inflammatory markers were associated with VL during the first 10 days of hospitalization, and several of these markers were associated with severe outcomes, in particular when combined with elevated VL. Future studies should assess the potential for combining antiviral and immunomodulatory treatment, preferably guided by viral and inflammatory biomarkers, for the selection of high‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19BiomarkersViral LoadHospitalizationSARS-CoV-2Severity of Illness IndexHumansMaleFemaleMiddle AgedAgedInflammationCytokines

Stichwörter der Autor:innen

SARS‐CoV‐2antiviral treatmentchemokinecytokineimmunomodulationindividualized treatmentpredictive markersrespiratory distress syndrome

Substanzen

BiomarkersCytokines

Autor:innen und Institutionen

  • Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Department of Anesthesia and Intensive Care Medicine, Oslo University Hospital, Oslo, Norway.
  • Division of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway.
  • Division of Laboratory Medicine, Department of Immunology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Andreas Barrat-Due, Trine Kåsine, Tøri Vigeland Lerum

Zitieren

APA

Viermyr, H. K., Halvorsen, B., Sagen, E. L., Michelsen, A. E., Barrat-Due, A., Kåsine, T., Nezvalova-Henriksen, K., Dyrhol-Riise, A. M., Nor‐Solidarity Consortium, Lerum, T. V., Müller, F., Tonby, K., Tveita, A., Aukrust, P., Trøseid, M., Ueland, T., & Dahl, T. B. (2024). High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial. Journal of Internal Medicine. https://doi.org/10.1111/joim.13820

Vancouver

Viermyr HK, Halvorsen B, Sagen EL, Michelsen AE, Barrat-Due A, Kåsine T, et al. High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial. Journal of Internal Medicine. 2024. doi:10.1111/joim.13820

BibTeX
@article{Viermyr2024,
  author = {Viermyr, Hans-Kittil and Halvorsen, Bente and Sagen, Ellen Lund and Michelsen, Annika E and Barrat-Due, Andreas and Kåsine, Trine and Nezvalova-Henriksen, Katerina and Dyrhol-Riise, Anne Ma and Nor‐Solidarity Consortium, Nor‐Solidarity Consortium and Lerum, Tøri Vigeland and Müller, Fredrik and Tonby, Kristian and Tveita, Anders and Aukrust, Pål and Trøseid, Marius and Ueland, Thor and Dahl, Tuva Børresdatter},
  title = {High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial},
  journal = {Journal of Internal Medicine},
  year = {2024},
  doi = {10.1111/joim.13820}
}
Kostenlos starten →